IBL-302
Product Specifications
CAS Number
1414455-21-2
Target
PI3K|||Akt|||mTOR|||Pim
Related Pathways
Cytoskeletal Signaling|||Chromatin/Epigenetic|||PI3K/Akt/mTOR signaling|||JAK/STAT signaling
Bioactivity
IBL-302 (AMU302), an orally available dual-signaling inhibitor targeting PIM and PI3K/AKT/mTOR, is effective against breast cancer and neuroblastoma. It has shown in vivo efficacy in a nude mouse xenograft model by combating trastuzumab resistance. Additionally, IBL-302 augments the effectiveness of widely used cytotoxic chemotherapy drugs such as cisplatin, doxorubicin, and etoposide [1] [2] [3].
Smiles
CC=1C2=C3C(C=4SC(=CC4)CNC(=O)C=5C=C(S(=O)(=O)NC6=CC(C1S3)=CN=C6OC)C=CC5F)=NC=N2
Molecular Formula
C25H18FN5O4S3
Molecular Weight
567.64
Shipping Conditions
Cool pack
Storage Temperature
-20°C
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
